Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments for severely disabling CNS and orphan disorders and reduce the attrition rate in clinical development. With an extensive portfolio of highly predictive disease models and unparalleled experience performing studies for biopharmaceutical companies of all sizes, we enable clients to deliver much needed superior clinical candidates to patients.